Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by THobsvon Sep 25, 2023 11:10am
159 Views
Post# 35652216

RE:RE:RE:New Press Release - Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility

RE:RE:RE:New Press Release - Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility

It is a lot to give up, and demonstrates how tough the initial terms were, but it does show Marathon's willingness to work with TH and this seems like a more complete restructuring of the agreement so that there is a sustainable way forward. Lenders hold all the cards in these situations. 

5% dilution at $55mm market cap stings, but reducing the liquidity requirements are an important and necessary change. Markets were contemplating a much more painful raise and/or worse outcome just a few weeks ago. I would like to hear more about what these adjusted EBITDA targets will be. In some way it's nice to have some discipline forced on management, but it is another leverage point for Marathon.

Submitting F8 is very good to see. Now let's see how they performed last quarter, how close to cash flow positive they are, and what their projections are. And perhaps at least hear that they have recruited a few patients for 1902.

 

<< Previous
Bullboard Posts
Next >>